AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ALGS · NASDAQ · Biotechnology

Aligos Therapeutics

Develops liver- and viral-disease drug candidates, including a chronic hepatitis B program.

$7.02

After-hours close+0.17 (+2.48%)

At close$6.85(−3.11%)

Something off on this page? Send us feedback.

Profile

Aligos Therapeutics, Inc.ALGSHealth Care

Develops drug candidates for liver and viral diseases, including a Phase 2 chronic hepatitis B program. The clinical-stage company has no product-sales revenue and relies on financing and license or collaboration payments to fund its pipeline.

Develops drug candidates for liver and viral diseases, including a chronic hepatitis B program evaluating pevifoscorvir sodium in a Phase 2 trial.

Founded in 2018, it has been led by co-founder Lawrence M. Blatt since formation and became a Nasdaq-listed company in 2020. Based in South San Francisco, it remains clinical-stage and reports no product-sales revenue. Research and development are supported by equity financing, license payments and collaborations.

An exclusive-license arrangement gives Xiamen Amoytop Biotech Greater China development and commercialization rights for pevifoscorvir sodium. Clinical development, financing and collaboration or licensing proceeds are central operating dependencies.

Company facts

CEOLawrence M. Blatt

ListedOct 16, 2020

ExchangeNASDAQ

HeadquartersSouth San Francisco, CA

CountryUnited States

Employees82

CIK0001799448

ISINUS01626L2043

Key statistics

Market cap$42.8M

EPS (ttm)−$7.30

P/E (ttm)−0.9466

ROE-160.7%

P/B2.26

P/S1.36

Dividend yield—

Beta1.39vs XLV 1.15

Year to date −25.0% · Average volume (30d) 128.1K

Analysts

Price target, next 12 months$20.00+189.4%Median of 5 analysts · vs the Aug 28 close

ConsensusBuy3 of 5 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $6.91

High$20.00+189.4%

Median$20.00+189.4%

Low$20.00+189.4%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Target
May 21, 2026	Cantor Fitzgerald	Target	$20
Jan 7, 2026	UBS	Target	$20

Earnings

EPS

Estimate−$2.44

ReportedDue Nov 5, 2026

Revenue

Estimate$4.9M

ReportedDue Nov 5, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 6, 2026Q2 FY26	−$1.09	−$0.14	+87.2%	$24.7M	$27.8M	+12.6%	+16.24%
May 7, 2026Q1 FY26	−$2.29	−$2.21	+3.5%	$250.0K	$2.8M	+1,032.0%	+6.80%
Mar 5, 2026Q4 FY25	−$2.49	−$1.91	+23.2%	$440.0K	$169.0K	−61.6%	+4.80%
Nov 6, 2025Q3 FY25	−$2.09	−$3.04	−45.5%	$266.7K	$741.0K	+177.9%	−0.42%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$311.0K	$965.0K	$741.0K	$169.0K	$2.8M	$27.8M
Gross profit	$311.0K	$706.0K	$741.0K	−$88.0K	$2.8M	$27.8M
Operating income	−$19.2M	−$18.6M	−$28.4M	−$21.8M	−$26.9M	−$1.9M
Net income	$43.1M	−$15.9M	−$31.5M	−$19.9M	−$23.0M	−$1.5M
Diluted EPS	$4.95	−$1.53	−$3.04	−$1.91	−$2.21	−$0.14
Gross margin	100.0%	73.2%	100.0%	-52.1%	100.0%	100.0%
Operating margin	-6,187.5%	-1,924.0%	-3,827.4%	-12,907.7%	-951.6%	-6.8%

Fiscal years (4-quarter sums)FY21 $4.4M · FY22 $13.9M · FY23 $15.5M · FY24 $3.9M · FY25 $2.2M

Balance sheet, Jun 30, 2026Cash & short-term investments $30.4M · Total debt $3.5M · Total assets $66.3M · Shareholders' equity $31.9M

Dividends

No dividends on record.

Ownership

Institutions 44.84%Insiders —

Shares outstanding 6.19M · Float 4.80M · 77.5% free float

Insiders — no current Form 4 position.

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Deep Track Capital, LP	444.1K	7.18%	13F	May 15, 2026
Alyeska Investment Group, L.P.	412.0K	6.66%	13F	May 15, 2026
Sio Capital Management, LLC	327.2K	5.29%	13F	May 14, 2026
Lawrence M. Blatt	316.2K	5.60%	13D	Jun 24, 2026
Marshall Wace, LLP	267.1K	4.32%	13F	May 15, 2026

Insider tradesForm 4

No open-market trades in the last 12 months.